GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery
Nuclear receptor-interacting protein 1 (Nuclear factor RIP140) (Receptor-interacting protein 140)
NRIP1_HUMAN Reviewed; 1158 AA.
P48552; Q8IWE8;
01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
01-DEC-2000, sequence version 2.
28-MAR-2018, entry version 161.
RecName: Full=Nuclear receptor-interacting protein 1;
AltName: Full=Nuclear factor RIP140;
AltName: Full=Receptor-interacting protein 140;
Name=NRIP1;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH ESR1,
SUBCELLULAR LOCATION, AND VARIANT GLY-448.
TISSUE=Mammary gland;
PubMed=7641693;
Cavailles V., Dauvois S., L'Horset F., Lopez G., Hoare S.,
Kushner P.J., Parker M.G.;
"Nuclear factor RIP140 modulates transcriptional activation by the
estrogen receptor.";
EMBO J. 14:3741-3751(1995).
[2]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=10830953; DOI=10.1038/35012518;
Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
Lehrach H., Reinhardt R., Yaspo M.-L.;
"The DNA sequence of human chromosome 21.";
Nature 405:311-319(2000).
[3]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Skin;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[4]
INTERACTION WITH NR2C2.
PubMed=9556573; DOI=10.1074/jbc.273.18.10948;
Yan Z.H., Karam W.G., Staudinger J.L., Medvedev A., Ghanayem B.I.,
Jetten A.M.;
"Regulation of peroxisome proliferator-activated receptor alpha-
induced transactivation by the nuclear orphan receptor TAK1/TR4.";
J. Biol. Chem. 273:10948-10957(1998).
[5]
FUNCTION, AND INTERACTION WITH NR3C1.
PubMed=10364267; DOI=10.1074/jbc.274.25.18121;
Subramaniam N., Treuter E., Okret S.;
"Receptor interacting protein RIP140 inhibits both positive and
negative gene regulation by glucocorticoids.";
J. Biol. Chem. 274:18121-18127(1999).
[6]
FUNCTION, INTERACTION WITH CTBP1, MUTAGENESIS OF 440-PRO--LEU-443 AND
LYS-446, AND ACETYLATION AT LYS-446.
PubMed=11509661; DOI=10.1128/MCB.21.18.6181-6188.2001;
Vo N., Fjeld C., Goodman R.H.;
"Acetylation of nuclear hormone receptor-interacting protein RIP140
regulates binding of the transcriptional corepressor CtBP.";
Mol. Cell. Biol. 21:6181-6188(2001).
[7]
INTERACTION WITH NR3C1 AND YWHAH, IDENTIFICATION IN A COMPLEX WITH
NR3C1 AND YWHAH, AND SUBCELLULAR LOCATION.
PubMed=11266503; DOI=10.1210/mend.15.4.0624;
Zilliacus J., Holter E., Wakui H., Tazawa H., Treuter E.,
Gustafsson J.-A.;
"Regulation of glucocorticoid receptor activity by 14-3-3-dependent
intracellular relocalization of the corepressor RIP140.";
Mol. Endocrinol. 15:501-511(2001).
[8]
FUNCTION, AND INTERACTION WITH NR3C2.
PubMed=11518808; DOI=10.1210/mend.15.9.0689;
Zennaro M.-C., Souque A., Viengchareun S., Poisson E., Lombes M.;
"A new human MR splice variant is a ligand-independent transactivator
modulating corticosteroid action.";
Mol. Endocrinol. 15:1586-1598(2001).
[9]
INTERACTION WITH NR3C1, AND SUBCELLULAR LOCATION.
PubMed=12773562; DOI=10.1128/MCB.23.12.4187-4198.2003;
Tazawa H., Osman W., Shoji Y., Treuter E., Gustafsson J.-A.,
Zilliacus J.;
"Regulation of subnuclear localization is associated with a mechanism
for nuclear receptor corepression by RIP140.";
Mol. Cell. Biol. 23:4187-4198(2003).
[10]
FUNCTION, AND INTERACTION WITH ESR1; FOS AND JUN.
PubMed=12554755; DOI=10.1210/me.2002-0324;
Teyssier C., Belguise K., Galtier F., Cavailles V., Chalbos D.;
"Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-
induced activator protein-1 activity by reversing glucocorticoid
receptor-interacting protein 1 effect.";
Mol. Endocrinol. 17:287-299(2003).
[11]
INTERACTION WITH CTBP1 AND CTBP2, MUTAGENESIS OF 442-ASP--LEU-443;
567-ASN--LEU-568 AND 948-ASP--LEU-949, AND IDENTIFICATION OF
REPRESSION DOMAINS.
PubMed=14736873; DOI=10.1074/jbc.M313906200;
Christian M., Tullet J.M.A., Parker M.G.;
"Characterization of four autonomous repression domains in the
corepressor receptor interacting protein 140.";
J. Biol. Chem. 279:15645-15651(2004).
[12]
FUNCTION, INTERACTION WITH CTBP1; CTBP2; HDAC1; HDAC2; HDAC5 AND
HDAC6, MUTAGENESIS OF 442-ASP--LEU-443 AND 567-ASN--LEU-568, AND
SUBCELLULAR LOCATION.
PubMed=15060175; DOI=10.1093/nar/gkh524;
Castet A., Boulahtouf A., Versini G., Bonnet S., Augereau P.,
Vignon F., Khochbin S., Jalaguier S., Cavailles V.;
"Multiple domains of the receptor-interacting protein 140 contribute
to transcription inhibition.";
Nucleic Acids Res. 32:1957-1966(2004).
[13]
INTERACTION WITH NR2C2.
PubMed=16887930; DOI=10.1074/mcp.M600180-MCP200;
Huq M.D., Gupta P., Tsai N.P., Wei L.N.;
"Modulation of testicular receptor 4 activity by mitogen-activated
protein kinase-mediated phosphorylation.";
Mol. Cell. Proteomics 5:2072-2082(2006).
[14]
INTERACTION WITH ZNF366.
PubMed=17085477; DOI=10.1093/nar/gkl875;
Lopez-Garcia J., Periyasamy M., Thomas R.S., Christian M., Leao M.,
Jat P., Kindle K.B., Heery D.M., Parker M.G., Buluwela L.,
Kamalati T., Ali S.;
"ZNF366 is an estrogen receptor corepressor that acts through CtBP and
histone deacetylases.";
Nucleic Acids Res. 34:6126-6136(2006).
[15]
FUNCTION, INTERACTION WITH RORA, AND INDUCTION.
PubMed=21628546; DOI=10.1177/0748730411401579;
Poliandri A.H., Gamsby J.J., Christian M., Spinella M.J., Loros J.J.,
Dunlap J.C., Parker M.G.;
"Modulation of clock gene expression by the transcriptional
coregulator receptor interacting protein 140 (RIP140).";
J. Biol. Rhythms 26:187-199(2011).
[16]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-564 AND SER-807, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Erythroleukemia;
PubMed=23186163; DOI=10.1021/pr300630k;
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
Mohammed S.;
"Toward a comprehensive characterization of a human cancer cell
phosphoproteome.";
J. Proteome Res. 12:260-271(2013).
[17]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-218; SER-671 AND
SER-807, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
ANALYSIS].
TISSUE=Liver;
PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
Wang L., Ye M., Zou H.;
"An enzyme assisted RP-RPLC approach for in-depth analysis of human
liver phosphoproteome.";
J. Proteomics 96:253-262(2014).
[18]
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-756 AND LYS-1105, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=25218447; DOI=10.1038/nsmb.2890;
Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
Vertegaal A.C.;
"Uncovering global SUMOylation signaling networks in a site-specific
manner.";
Nat. Struct. Mol. Biol. 21:927-936(2014).
[19]
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-111; LYS-170; LYS-195;
LYS-198; LYS-372; LYS-508; LYS-756; LYS-802; LYS-850; LYS-901;
LYS-931; LYS-1105; LYS-1115 AND LYS-1154, AND IDENTIFICATION BY MASS
SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=28112733; DOI=10.1038/nsmb.3366;
Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
Nielsen M.L.;
"Site-specific mapping of the human SUMO proteome reveals co-
modification with phosphorylation.";
Nat. Struct. Mol. Biol. 24:325-336(2017).
[20]
X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 366-390 IN COMPLEX WITH
ESRRG.
PubMed=16990259; DOI=10.1074/jbc.M608410200;
Wang L., Zuercher W.J., Consler T.G., Lambert M.H., Miller A.B.,
Orband-Miller L.A., McKee D.D., Willson T.M., Nolte R.T.;
"X-ray crystal structures of the estrogen-related receptor-gamma
ligand binding domain in three functional states reveal the molecular
basis of small molecule regulation.";
J. Biol. Chem. 281:37773-37781(2006).
[21]
VARIANTS ARG-221; VAL-441; GLY-448; LEU-803 AND PHE-1079.
PubMed=16131398; DOI=10.1186/1743-1050-2-11;
Caballero V., Ruiz R., Sainz J.A., Cruz M., Lopez-Nevot M.A.,
Galan J.J., Real L.M., de Castro F., Lopez-Villaverde V., Ruiz A.;
"Preliminary molecular genetic analysis of the receptor interacting
protein 140 (RIP140) in women affected by endometriosis.";
J. Exp. Clin. Assist. Reprod. 2:11-11(2005).
-!- FUNCTION: Modulates transcriptional activation by steroid
receptors such as NR3C1, NR3C2 and ESR1. Also modulates
transcriptional repression by nuclear hormone receptors. Positive
regulator of the circadian clock gene expression: stimulates
transcription of ARNTL/BMAL1, CLOCK and CRY1 by acting as a
coactivator for RORA and RORC. {ECO:0000269|PubMed:10364267,
ECO:0000269|PubMed:11509661, ECO:0000269|PubMed:11518808,
ECO:0000269|PubMed:12554755, ECO:0000269|PubMed:15060175,
ECO:0000269|PubMed:21628546, ECO:0000269|PubMed:7641693}.
-!- SUBUNIT: Interacts with RARA and RXRB homodimers and RARA/RXRB
heterodimers in the presence of ligand. Interacts with HDAC1 and
HDAC3 via its N-terminal domain. Interacts with NR2C1 (sumoylated
form and via the ligand-binding domain); the interaction results
in promoting the repressor activity of NR2C1 (By similarity).
Interacts with CTBP1, CTBP2, ESR1, HDAC1, HDAC2, HDAC5, HDAC6,
NR2C2, NR3C1, NR3C2, YWHAH, JUN and FOS. Found in a complex with
both NR3C1 and YWHAH. Interacts with ZNF366. Interacts with RORA.
{ECO:0000250|UniProtKB:Q8CBD1, ECO:0000269|PubMed:10364267,
ECO:0000269|PubMed:11266503, ECO:0000269|PubMed:11509661,
ECO:0000269|PubMed:11518808, ECO:0000269|PubMed:12554755,
ECO:0000269|PubMed:12773562, ECO:0000269|PubMed:14736873,
ECO:0000269|PubMed:15060175, ECO:0000269|PubMed:16887930,
ECO:0000269|PubMed:16990259, ECO:0000269|PubMed:17085477,
ECO:0000269|PubMed:21628546, ECO:0000269|PubMed:7641693,
ECO:0000269|PubMed:9556573}.
-!- INTERACTION:
O15145:ARPC3; NbExp=3; IntAct=EBI-746484, EBI-351829;
Q8NHQ1:CEP70; NbExp=3; IntAct=EBI-746484, EBI-739624;
P26358:DNMT1; NbExp=3; IntAct=EBI-746484, EBI-719459;
Q13642:FHL1; NbExp=6; IntAct=EBI-746484, EBI-912547;
O15379:HDAC3; NbExp=2; IntAct=EBI-746484, EBI-607682;
O95751:LDOC1; NbExp=3; IntAct=EBI-746484, EBI-740738;
Q99873:PRMT1; NbExp=4; IntAct=EBI-746484, EBI-78738;
P10276:RARA; NbExp=4; IntAct=EBI-746484, EBI-413374;
P10276-2:RARA; NbExp=3; IntAct=EBI-746484, EBI-10197061;
Q8N895:ZNF366; NbExp=2; IntAct=EBI-746484, EBI-2813661;
-!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11266503,
ECO:0000269|PubMed:12773562, ECO:0000269|PubMed:15060175,
ECO:0000269|PubMed:7641693}. Note=Localized to discrete foci and
redistributes to larger nuclear domains upon binding to ligand-
bound NR3C1.
-!- INDUCTION: Expressed in a circadian manner in the liver (at
protein level). {ECO:0000269|PubMed:21628546}.
-!- DOMAIN: Contains 9 Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs, which have
different affinities for nuclear receptors. The C-terminal
LTKTNPILYYMLQK motif is required for ligand-dependent interaction
with RAAR and RXRB homodimers and heterodimers, for the
corepressor activity, and for the formation of an HDAC3 complex
with RARA/RXRB (By similarity). Contains at least four autonomous
repression domains (RD1-4). RD1 functions via a histone
deacetylase (HDAC)-independent mechanism, whereas RD2, RD3 and RD4
can function by HDAC-dependent or independent mechanisms,
depending on cell type. RD2 is dependent on CTBP binding.
{ECO:0000250}.
-!- PTM: Acetylation regulates its nuclear translocation and
corepressive activity (By similarity). Acetylation abolishes
interaction with CTBP1. Phosphorylation enhances interaction with
YWHAH. {ECO:0000250, ECO:0000269|PubMed:11509661}.
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/NRIP1ID44067ch21q11.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; X84373; CAA59108.1; -; mRNA.
EMBL; AF248484; AAF62185.1; -; Genomic_DNA.
EMBL; AF127577; AAF35255.1; -; Genomic_DNA.
EMBL; AL163207; CAB90396.1; -; Genomic_DNA.
EMBL; BC040361; AAH40361.1; -; mRNA.
CCDS; CCDS13568.1; -.
PIR; S57348; S57348.
RefSeq; NP_003480.2; NM_003489.3.
RefSeq; XP_005261120.1; XM_005261063.3.
RefSeq; XP_005261122.1; XM_005261065.3.
RefSeq; XP_011528049.1; XM_011529747.1.
RefSeq; XP_011528050.1; XM_011529748.2.
RefSeq; XP_011528051.1; XM_011529749.2.
RefSeq; XP_011528053.1; XM_011529751.2.
RefSeq; XP_011528054.1; XM_011529752.1.
RefSeq; XP_016883962.1; XM_017028473.1.
RefSeq; XP_016883963.1; XM_017028474.1.
RefSeq; XP_016883964.1; XM_017028475.1.
RefSeq; XP_016883965.1; XM_017028476.1.
UniGene; Hs.155017; -.
PDB; 2GPO; X-ray; 1.95 A; C=366-390.
PDB; 2GPP; X-ray; 2.60 A; C/D=366-390.
PDB; 4S14; X-ray; 3.54 A; C=499-510.
PDB; 4S15; X-ray; 1.90 A; C/D=499-510.
PDB; 5NTI; X-ray; 2.40 A; P/Q/R/S=493-512.
PDB; 5NTN; X-ray; 1.90 A; P/Q/R/S=493-512.
PDB; 5NTW; X-ray; 1.64 A; P/Q/R/S=493-512.
PDB; 5NU1; X-ray; 1.85 A; P/Q=493-512.
PDBsum; 2GPO; -.
PDBsum; 2GPP; -.
PDBsum; 4S14; -.
PDBsum; 4S15; -.
PDBsum; 5NTI; -.
PDBsum; 5NTN; -.
PDBsum; 5NTW; -.
PDBsum; 5NU1; -.
ProteinModelPortal; P48552; -.
SMR; P48552; -.
BioGrid; 113843; 58.
DIP; DIP-5964N; -.
IntAct; P48552; 27.
MINT; P48552; -.
STRING; 9606.ENSP00000327213; -.
DrugBank; DB06884; 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE.
iPTMnet; P48552; -.
PhosphoSitePlus; P48552; -.
BioMuta; NRIP1; -.
DMDM; 9988061; -.
EPD; P48552; -.
MaxQB; P48552; -.
PaxDb; P48552; -.
PeptideAtlas; P48552; -.
PRIDE; P48552; -.
DNASU; 8204; -.
Ensembl; ENST00000318948; ENSP00000327213; ENSG00000180530.
Ensembl; ENST00000400199; ENSP00000383060; ENSG00000180530.
Ensembl; ENST00000400202; ENSP00000383063; ENSG00000180530.
GeneID; 8204; -.
KEGG; hsa:8204; -.
UCSC; uc002yjx.2; human.
CTD; 8204; -.
DisGeNET; 8204; -.
EuPathDB; HostDB:ENSG00000180530.9; -.
GeneCards; NRIP1; -.
H-InvDB; HIX0027827; -.
HGNC; HGNC:8001; NRIP1.
HPA; HPA046571; -.
HPA; HPA060036; -.
MIM; 602490; gene.
neXtProt; NX_P48552; -.
OpenTargets; ENSG00000180530; -.
PharmGKB; PA31780; -.
eggNOG; ENOG410IFW7; Eukaryota.
eggNOG; ENOG410XPVS; LUCA.
GeneTree; ENSGT00390000007999; -.
HOGENOM; HOG000236277; -.
HOVERGEN; HBG052667; -.
InParanoid; P48552; -.
KO; K17965; -.
OMA; YMLQKGG; -.
OrthoDB; EOG091G07UX; -.
PhylomeDB; P48552; -.
TreeFam; TF332210; -.
Reactome; R-HSA-1368082; RORA activates gene expression.
Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
Reactome; R-HSA-400253; Circadian Clock.
SignaLink; P48552; -.
SIGNOR; P48552; -.
ChiTaRS; NRIP1; human.
EvolutionaryTrace; P48552; -.
GeneWiki; NRIP1; -.
GenomeRNAi; 8204; -.
PRO; PR:P48552; -.
Proteomes; UP000005640; Chromosome 21.
Bgee; ENSG00000180530; -.
CleanEx; HS_NRIP1; -.
ExpressionAtlas; P48552; baseline and differential.
Genevisible; P48552; HS.
GO; GO:0000118; C:histone deacetylase complex; IEA:Ensembl.
GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
GO; GO:0005730; C:nucleolus; IDA:HPA.
GO; GO:0005634; C:nucleus; IDA:UniProtKB.
GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:UniProtKB.
GO; GO:0030331; F:estrogen receptor binding; IPI:UniProtKB.
GO; GO:0035259; F:glucocorticoid receptor binding; IPI:UniProtKB.
GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
GO; GO:0035257; F:nuclear hormone receptor binding; IPI:UniProtKB.
GO; GO:0046965; F:retinoid X receptor binding; IEA:Ensembl.
GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:BHF-UCL.
GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
GO; GO:0007623; P:circadian rhythm; IEP:UniProtKB.
GO; GO:0019915; P:lipid storage; IEA:Ensembl.
GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
GO; GO:0001543; P:ovarian follicle rupture; IEA:Ensembl.
GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
InterPro; IPR026649; NRIP1.
InterPro; IPR031405; NRIP1_RD1.
InterPro; IPR031406; NRIP1_RD2.
InterPro; IPR031407; NRIP1_RD3.
InterPro; IPR031408; NRIP1_RD4.
PANTHER; PTHR15088; PTHR15088; 1.
Pfam; PF15687; NRIP1_repr_1; 1.
Pfam; PF15688; NRIP1_repr_2; 1.
Pfam; PF15689; NRIP1_repr_3; 1.
Pfam; PF15690; NRIP1_repr_4; 1.
1: Evidence at protein level;
3D-structure; Acetylation; Activator; Biological rhythms;
Complete proteome; Isopeptide bond; Nucleus; Phosphoprotein;
Polymorphism; Reference proteome; Repeat; Transcription;
Transcription regulation; Ubl conjugation.
CHAIN 1 1158 Nuclear receptor-interacting protein 1.
/FTId=PRO_0000057951.
REGION 1 415 Interaction with ZNF366.
{ECO:0000269|PubMed:17085477}.
REGION 78 333 Repression domain 1.
REGION 410 700 Repression domain 2.
REGION 431 472 Required for targeting to small nuclear
foci.
REGION 735 885 Repression domain 3.
REGION 753 1158 Interaction with ZNF366.
{ECO:0000269|PubMed:17085477}.
REGION 1118 1158 Repression domain 4.
MOTIF 21 25 LXXLL motif 1.
MOTIF 133 137 LXXLL motif 2.
MOTIF 185 189 LXXLL motif 3.
MOTIF 266 270 LXXLL motif 4.
MOTIF 380 384 LXXLL motif 5.
MOTIF 440 446 CTBP-binding; principal site.
MOTIF 500 504 LXXLL motif 6.
MOTIF 565 569 CTBP-binding.
MOTIF 599 603 CTBP-binding. {ECO:0000255}.
MOTIF 713 717 LXXLL motif 7.
MOTIF 819 823 LXXLL motif 8.
MOTIF 936 940 LXXLL motif 9.
MOTIF 946 950 CTBP-binding.
MOTIF 1061 1074 Ligand-dependent nuclear receptor
binding. {ECO:0000250}.
MOD_RES 104 104 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 111 111 N6-acetyllysine; alternate.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 158 158 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 207 207 Phosphothreonine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 218 218 Phosphoserine.
{ECO:0000244|PubMed:24275569}.
MOD_RES 286 286 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 310 310 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 356 356 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 378 378 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 446 446 N6-acetyllysine.
{ECO:0000269|PubMed:11509661}.
MOD_RES 481 481 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 487 487 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 518 518 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 528 528 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 542 542 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 564 564 Phosphoserine.
{ECO:0000244|PubMed:23186163}.
MOD_RES 606 606 N6-acetyllysine.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 671 671 Phosphoserine.
{ECO:0000244|PubMed:24275569}.
MOD_RES 807 807 Phosphoserine.
{ECO:0000244|PubMed:23186163,
ECO:0000244|PubMed:24275569}.
MOD_RES 931 931 N6-acetyllysine; alternate.
{ECO:0000250|UniProtKB:Q8CBD1}.
MOD_RES 1001 1001 Phosphoserine.
{ECO:0000250|UniProtKB:Q8CBD1}.
CROSSLNK 111 111 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2);
alternate. {ECO:0000244|PubMed:28112733}.
CROSSLNK 170 170 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 195 195 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 198 198 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 372 372 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 508 508 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 756 756 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:25218447,
ECO:0000244|PubMed:28112733}.
CROSSLNK 802 802 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 850 850 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 901 901 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 931 931 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2);
alternate. {ECO:0000244|PubMed:28112733}.
CROSSLNK 1105 1105 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:25218447,
ECO:0000244|PubMed:28112733}.
CROSSLNK 1115 1115 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
CROSSLNK 1154 1154 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2).
{ECO:0000244|PubMed:28112733}.
VARIANT 37 37 V -> I (in dbSNP:rs9941840).
/FTId=VAR_051241.
VARIANT 221 221 H -> R (in dbSNP:rs139263261).
{ECO:0000269|PubMed:16131398}.
/FTId=VAR_023706.
VARIANT 315 315 Y -> F (in dbSNP:rs2228507).
/FTId=VAR_034142.
VARIANT 441 441 I -> V (in dbSNP:rs150468995).
{ECO:0000269|PubMed:16131398}.
/FTId=VAR_023707.
VARIANT 448 448 R -> G (common polymorphism;
dbSNP:rs2229742).
{ECO:0000269|PubMed:16131398,
ECO:0000269|PubMed:7641693}.
/FTId=VAR_023708.
VARIANT 567 567 N -> S (in dbSNP:rs9975169).
/FTId=VAR_051242.
VARIANT 803 803 S -> L (in dbSNP:rs61750208).
{ECO:0000269|PubMed:16131398}.
/FTId=VAR_023709.
VARIANT 1079 1079 V -> F (in dbSNP:rs140803495).
{ECO:0000269|PubMed:16131398}.
/FTId=VAR_023710.
MUTAGEN 440 443 PIDL->AAAA: Abolishes interaction with
CTBP1. {ECO:0000269|PubMed:11509661}.
MUTAGEN 440 442 PID->AIA: Abolishes interaction with
CTBP1 and attenuates nuclear hormone
receptor-dependent transcription
repression.
MUTAGEN 442 443 DL->AA: Reduces, but does not completely
abolish, interaction with CTBP. Reduces
transcriptional repression.
{ECO:0000269|PubMed:14736873,
ECO:0000269|PubMed:15060175}.
MUTAGEN 442 443 DL->AS: Disrupts interaction with CTBP1,
and CTBP2 to a lesser extent. Disrupts
transcriptional repression; when
associated with 567-AS-568.
{ECO:0000269|PubMed:14736873,
ECO:0000269|PubMed:15060175}.
MUTAGEN 446 446 K->Q: Disrupts interaction with CTBP1.
Decreases lysine acetylation. Disrupts
nuclear hormone receptor-dependent
transcription repression.
{ECO:0000269|PubMed:11509661}.
MUTAGEN 446 446 K->R: Does not disrupt nuclear hormone
receptor-dependent transcription
repression.
{ECO:0000269|PubMed:11509661}.
MUTAGEN 567 568 NL->AA: Disrupts transcriptional
repression. {ECO:0000269|PubMed:14736873,
ECO:0000269|PubMed:15060175}.
MUTAGEN 567 568 NL->AS: Disrupts interaction with CTBP1
and CTBP2. Disrupts transcriptional
repression; when associated with 442-AS-
443. {ECO:0000269|PubMed:14736873,
ECO:0000269|PubMed:15060175}.
MUTAGEN 599 603 SMDLT->PIAAS: Does not further disrupt
transcriptional repression; when
associated with 442-AA-443 and 567-AA-
568.
MUTAGEN 948 949 DL->AA: Abolishes CTBP binding but
retains transcriptional repressor
activity. {ECO:0000269|PubMed:14736873}.
CONFLICT 124 124 P -> R (in Ref. 1; CAA59108).
{ECO:0000305}.
CONFLICT 721 726 NKGKSE -> TKGRVK (in Ref. 1; CAA59108).
{ECO:0000305}.
CONFLICT 954 954 S -> I (in Ref. 3; AAH40361).
{ECO:0000305}.
CONFLICT 1080 1080 T -> A (in Ref. 1; CAA59108).
{ECO:0000305}.
HELIX 379 385 {ECO:0000244|PDB:2GPO}.
HELIX 500 505 {ECO:0000244|PDB:5NTW}.
SEQUENCE 1158 AA; 126942 MW; 81FC424968E9A5F6 CRC64;
MTHGEELGSD VHQDSIVLTY LEGLLMHQAA GGSGTAVDKK SAGHNEEDQN FNISGSAFPT
CQSNGPVLNT HTYQGSGMLH LKKARLLQSS EDWNAAKRKR LSDSIMNLNV KKEALLAGMV
DSVPKGKQDS TLLASLLQSF SSRLQTVALS QQIRQSLKEQ GYALSHDSLK VEKDLRCYGV
ASSHLKTLLK KSKVKDQKPD TNLPDVTKNL IRDRFAESPH HVGQSGTKVM SEPLSCAARL
QAVASMVEKR ASPATSPKPS VACSQLALLL SSEAHLQQYS REHALKTQNA NQAASERLAA
MARLQENGQK DVGSYQLPKG MSSHLNGQAR TSSSKLMASK SSATVFQNPM GIIPSSPKNA
GYKNSLERNN IKQAANNSLL LHLLKSQTIP KPMNGHSHSE RGSIFEESST PTTIDEYSDN
NPSFTDDSSG DESSYSNCVP IDLSCKHRTE KSESDQPVSL DNFTQSLLNT WDPKVPDVDI
KEDQDTSKNS KLNSHQKVTL LQLLLGHKNE ENVEKNTSPQ GVHNDVSKFN TQNYARTSVI
ESPSTNRTTP VSTPPLLTSS KAGSPINLSQ HSLVIKWNSP PYVCSTQSEK LTNTASNHSM
DLTKSKDPPG EKPAQNEGAQ NSATFSASKL LQNLAQCGMQ SSMSVEEQRP SKQLLTGNTD
KPIGMIDRLN SPLLSNKTNA VEENKAFSSQ PTGPEPGLSG SEIENLLERR TVLQLLLGNP
NKGKSEKKEK TPLRDESTQE HSERALSEQI LMVKIKSEPC DDLQIPNTNV HLSHDAKSAP
FLGMAPAVQR SAPALPVSED FKSEPVSPQD FSFSKNGLLS RLLRQNQDSY LADDSDRSHR
NNEMALLESK NLCMVPKKRK LYTEPLENPF KKMKNNIVDA ANNHSAPEVL YGSLLNQEEL
KFSRNDLEFK YPAGHGSASE SEHRSWARES KSFNVLKQLL LSENCVRDLS PHRSNSVADS
KKKGHKNNVT NSKPEFSISS LNGLMYSSTQ PSSCMDNRTF SYPGVVKTPV SPTFPEHLGC
AGSRPESGLL NGCSMPSEKG PIKWVITDAE KNEYEKDSPR LTKTNPILYY MLQKGGNSVT
SRETQDKDIW REASSAESVS QVTAKEELLP TAETKASFFN LRSPYNSHMG NNASRPHSAN
GEVYGLLGSV LTIKKESE
Related products :
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Pathways :
WP1502: Mitochondrial biogenesis
WP2272: Pathogenic Escherichia coli infection
WP2292: Chemokine signaling pathway
WP1046: Signaling of Hepatocyte Growth Factor Receptor
WP1162: Signaling of Hepatocyte Growth Factor Receptor
WP1206: Signaling of Hepatocyte Growth Factor Receptor
WP1235: Signaling of Hepatocyte Growth Factor Receptor
WP193: Signaling of Hepatocyte Growth Factor Receptor
WP313: Signaling of Hepatocyte Growth Factor Receptor
WP444: Signaling of Hepatocyte Growth Factor Receptor
WP810: Signaling of Hepatocyte Growth Factor Receptor
WP927: Signaling of Hepatocyte Growth Factor Receptor
WP94: Signaling of Hepatocyte Growth Factor Receptor
WP1004: Kit Receptor Signaling Pathway
WP1011: T Cell Receptor Signaling Pathway
WP1014: Androgen receptor signaling pathway
WP1025: B Cell Receptor Signaling Pathway
WP1045: TGF-beta Receptor Signaling Pathway
WP1049: G Protein Signaling Pathways
WP1067: Toll-like receptor signaling pathway
WP1068: Nuclear Receptors
WP1099: Nuclear receptors in lipid metabolism and toxicity
WP1112: EPO Receptor Signaling
WP1121: Kit Receptor Signaling Pathway
WP1130: T Cell Receptor Signaling Pathway
Related Genes :
[NR4A1 GFRP1 HMR NAK1] Nuclear receptor subfamily 4 group A member 1 (Early response protein NAK1) (Nuclear hormone receptor NUR/77) (Nur77) (Orphan nuclear receptor HMR) (Orphan nuclear receptor TR3) (ST-59) (Testicular receptor 3)
[Nr4a2 Hzf-3 Nurr1 Rnr1] Nuclear receptor subfamily 4 group A member 2 (NUR-related factor 1) (Nuclear orphan receptor HZF-3) (Orphan nuclear receptor NURR1) (Regenerating liver nuclear receptor 1) (RNR-1) (SL-322)
[Nr4a1 Gfrp Hmr N10 Nur77] Nuclear receptor subfamily 4 group A member 1 (Nuclear hormone receptor NUR/77) (Nuclear protein N10) (Orphan nuclear receptor HMR)
[EBNA-LP EBNA5] Epstein-Barr nuclear antigen leader protein (EBNA-LP) (EBV nuclear antigen leader protein) (Epstein-Barr nuclear antigen 5) (EBNA-5) (EBV nuclear antigen 5)
[NUP98 ADAR2] Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (98 kDa nucleoporin) (Nucleoporin Nup98) (Nup98); Nuclear pore complex protein Nup96 (96 kDa nucleoporin) (Nucleoporin Nup96) (Nup96)]
[Nup98] Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (98 kDa nucleoporin) (Nucleoporin Nup98) (Nup98); Nuclear pore complex protein Nup96 (96 kDa nucleoporin) (Nucleoporin Nup96) (Nup96)]
[Nup98] Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (98 kDa nucleoporin) (Nucleoporin Nup98) (Nup98); Nuclear pore complex protein Nup96 (96 kDa nucleoporin) (Nucleoporin Nup96) (Nup96)]
[Nup98-96 Nup145 Nup98 CG10198] Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (Nucleoporin Nup98) (Nup98); Nuclear pore complex protein Nup96 (Nucleoporin Nup96) (Nup96)]
[npp-10 ZK328.5] Nuclear pore complex protein Nup98-Nup96 (EC 3.4.21.-) [Cleaved into: Nuclear pore complex protein Nup98 (98 kDa nucleoporin) (Nucleoporin Nup98) (CeNup98); Nuclear pore complex protein Nup96 (96 kDa nucleoporin) (Nucleoporin Nup96) (CeNup96)]
[SYNE1 C6orf98 KIAA0796 KIAA1262 KIAA1756 MYNE1] Nesprin-1 (Enaptin) (KASH domain-containing protein 1) (KASH1) (Myocyte nuclear envelope protein 1) (Myne-1) (Nuclear envelope spectrin repeat protein 1) (Synaptic nuclear envelope protein 1) (Syne-1)
[NR1I2 PXR] Nuclear receptor subfamily 1 group I member 2 (Orphan nuclear receptor PAR1) (Orphan nuclear receptor PXR) (Pregnane X receptor) (Steroid and xenobiotic receptor) (SXR)
[Syne1] Nesprin-1 (Enaptin) (KASH domain-containing protein 1) (KASH1) (Myocyte nuclear envelope protein 1) (Myne-1) (Nuclear envelope spectrin repeat protein 1) (Synaptic nuclear envelope protein 1) (Syne-1)
[NUMA1 NMP22 NUMA] Nuclear mitotic apparatus protein 1 (Nuclear matrix protein-22) (NMP-22) (Nuclear mitotic apparatus protein) (NuMA protein) (SP-H antigen)
[NR4A2 NOT NURR1 TINUR] Nuclear receptor subfamily 4 group A member 2 (Immediate-early response protein NOT) (Orphan nuclear receptor NURR1) (Transcriptionally-inducible nuclear receptor)
[NR2E3 PNR RNR] Photoreceptor-specific nuclear receptor (Nuclear receptor subfamily 2 group E member 3) (Retina-specific nuclear receptor)
[NUP210 KIAA0906 PSEC0245] Nuclear pore membrane glycoprotein 210 (Nuclear pore protein gp210) (Nuclear envelope pore membrane protein POM 210) (POM210) (Nucleoporin Nup210) (Pore membrane protein of 210 kDa)
[RORA NR1F1 RZRA] Nuclear receptor ROR-alpha (Nuclear receptor RZR-alpha) (Nuclear receptor subfamily 1 group F member 1) (RAR-related orphan receptor A) (Retinoid-related orphan receptor-alpha)
[Rora Nr1f1 Rzra] Nuclear receptor ROR-alpha (Nuclear receptor RZR-alpha) (Nuclear receptor subfamily 1 group F member 1) (RAR-related orphan receptor A) (Retinoid-related orphan receptor-alpha)
[Nr2e3 Pnr Rnr] Photoreceptor-specific nuclear receptor (Nuclear receptor subfamily 2 group E member 3) (Retina-specific nuclear receptor)
[NCOA6 AIB3 KIAA0181 RAP250 TRBP] Nuclear receptor coactivator 6 (Activating signal cointegrator 2) (ASC-2) (Amplified in breast cancer protein 3) (Cancer-amplified transcriptional coactivator ASC-2) (Nuclear receptor coactivator RAP250) (NRC RAP250) (Nuclear receptor-activating protein, 250 kDa) (Peroxisome proliferator-activated receptor-interacting protein) (PPAR-interacting protein) (PRIP) (Thyroid hormone receptor-binding protein)
[Nr2c2 Mtr2r1 Tak1 Tr4] Nuclear receptor subfamily 2 group C member 2 (Orphan nuclear receptor TAK1) (Orphan nuclear receptor TR4) (Testicular receptor 4)
[Rorc Nr1f3 Rorg Thor] Nuclear receptor ROR-gamma (Nuclear receptor RZR-gamma) (Nuclear receptor subfamily 1 group F member 3) (RAR-related orphan receptor C) (Retinoid-related orphan receptor-gamma) (Thymus orphan receptor) (TOR)
[NR2C2 TAK1 TR4] Nuclear receptor subfamily 2 group C member 2 (Orphan nuclear receptor TAK1) (Orphan nuclear receptor TR4) (Testicular receptor 4)
[NR4A3 CHN CSMF MINOR NOR1 TEC] Nuclear receptor subfamily 4 group A member 3 (Mitogen-induced nuclear orphan receptor) (Neuron-derived orphan receptor 1) (Nuclear hormone receptor NOR-1)
[Nup210 Gp210 Pom210] Nuclear pore membrane glycoprotein 210 (Nuclear pore protein gp210) (Nuclear envelope pore membrane protein POM 210) (POM210) (Nucleoporin Nup210) (Pore membrane protein of 210 kDa)
[RORC NR1F3 RORG RZRG] Nuclear receptor ROR-gamma (Nuclear receptor RZR-gamma) (Nuclear receptor subfamily 1 group F member 3) (RAR-related orphan receptor C) (Retinoid-related orphan receptor-gamma)
[Ncoa6 Aib3 Rap250 Trbp] Nuclear receptor coactivator 6 (Activating signal cointegrator 2) (ASC-2) (Amplified in breast cancer protein 3) (Cancer-amplified transcriptional coactivator ASC-2) (Nuclear receptor coactivator RAP250) (NRC) (Nuclear receptor-activating protein, 250 kDa) (Peroxisome proliferator-activated receptor-interacting protein) (PPAR-interacting protein) (PRIP) (Thyroid hormone receptor-binding protein) (Fragment)
[CALCOCO2 NDP52] Calcium-binding and coiled-coil domain-containing protein 2 (Antigen nuclear dot 52 kDa protein) (Nuclear domain 10 protein NDP52) (Nuclear domain 10 protein 52) (Nuclear dot protein 52)
[Rorb Nr1f2 Rzrb] Nuclear receptor ROR-beta (Nuclear receptor RZR-beta) (Nuclear receptor subfamily 1 group F member 2) (Retinoid-related orphan receptor-beta)
[NFKB1] Nuclear factor NF-kappa-B p105 subunit (DNA-binding factor KBF1) (EBP-1) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) [Cleaved into: Nuclear factor NF-kappa-B p50 subunit]
Bibliography :
No related Items
Enter catalog number :
Favorites Pages:
No Favorits